Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor

Friday, Feb 08, 2019

Taiho Pharmaceutical Co., Ltd. and Cullinan Oncology, LLC announced on February 5 an agreement to develop TAS6417, a novel EGFR tyrosine kinase inhibitor ("epidermal growth factor receptor"). epidermal growth factor receptor ") discovered by Taiho Pharmaceutical.

Under the terms of the agreement, Taiho Pharmaceutical will grant Cullinan Pearl , a newly formed American company under the umbrella of Cullinan Oncology, an exclusive worldwide license, excluding Japan, for the development and commercialization of TAS6417. Taiho Pharmaceutical will receive an upfront payment, payments corresponding to regulatory and commercial milestones, as well as royalties based on net sales. Taiho Ventures, LLC, Cullinan Oncology Group's strategic venture capital arm, will fund Cullinan Pearl's A Series .

"Taiho's drug research team has created a unique molecule targeting EGFR exon 20 insertion mutations using the patented technology of its drug discovery platform. This alliance, one of the first of its kind at Taiho Pharmaceutical, allows our organization to optimize the allocation of its research and development resources and accelerate its global development giving it access to external resources and talent. We are excited to partner with Cullinan Oncology and its experienced management team to bring this innovative treatment to patients with NSCLC, "said Teruhiro Utsugi , General Manager of Taiho Pharmaceutical.

Cullinan Pearl will use Cullinan Oncology's shared services platform to develop TAS6417, which is based on a central management team and an integrated network of collaborators to contribute to the development of preclinical and clinical assets.

"We are excited to be working with Taiho Pharmaceutical and Taiho Ventures to explore the utility of this new drug in a patient population with limited options. We thank Taiho for having confidence in our team's ability to implement the clinical development of this exciting asset, "said Owen Hughes , CEO of Cullinan Oncology.



Other News